FOX reported that the nasal mist actually has the live virus in it. The vaccine doesn’t, so the doctor on the show said...
I believe the official story is that the nasal version of the vaccine has live, attenuated vaccine. But the injected vaccine carries only dead virus. The official story on this is quite consistent in all stories I have seen.
But some folks worry that it is not quite the case. Probably tinfoil hat stuff, but these days, one never really knows ...
HHS Awards MedImmune Contract to Manufacture Live Attenuated Nasal Spray Vaccine for H1N1
06/02/2009
MedImmune announces that the U.S. Department of Health and Human Services (HHS) has awarded the company a contract to manufacture monovalent (single-strain) live attenuated influenza vaccine for novel influenza A (H1N1) to vaccinate priority populations identified by HHS in the National Strategy for Pandemic Influenza. An initial order of $90 million of vaccine has been placed, with the potential for additional orders. This project has been funded in whole or in part with the Federal funds from HHS/ASPR/BARDA, under Contract No. HHSO100200900002I.
MedImmune scientists have identified several promising vaccine candidates against the novel influenza A (H1N1) strain, and are currently evaluating their growth properties and antigenicity (i.e., their ability to stimulate antibodies) for mass production as part of the vaccine manufacturing process.
“MedImmune is pleased to be able to contribute our scientific expertise in influenza vaccine development and manufacturing to help combat this unpredictable public health threat,” said Ben Machielse, executive vice president of operations at MedImmune. “We are confident that our vaccine technology has several attributes that may be useful in protecting people with limited exposure to influenza against the novel influenza A (H1N1) strain.”
MedImmune’s live attenuated influenza vaccine (LAIV) technology may be particularly well-suited for vaccinating against emerging influenza strains. LAIV is different from the injectable influenza vaccine in that it is a gentle mist sprayed into the nose, where the influenza virus usually enters the body. It contains live vaccine virus strains that are weakened so as not to cause the flu, but prompt the body to mount an immune response after the first dose. Because it is live and stimulates a broad range of immune responses, LAIV may offer some cross-protection against circulating flu strains that are “drifted” – meaning they are very closely-related but not perfectly matched to the flu strains in the vaccine. As a needle-free nasal spray, LAIV is well suited to facilitate mass vaccination, and has been widely used for school-based vaccinations and to help protect active-duty military personnel.
http://www.infectioncontroltoday.com/hotnews/medimmune-live-attenuated-h1n1-vaccine.html
AstraZeneca’s MedImmune to deliver additional H1N1 vaccines in USA
Tue. September 22, 2009; Posted: 09:23 AM
Dublin, Sep 22, 2009 (M2 PRESSWIRE via COMTEX) — MEDI | Quote | Chart | News | PowerRating — 22 September 2009 - US firm MedImmune Inc, a subsidiary of Anglo-Swedish pharma major AstraZeneca (LON:AZN) (NYSE:AZN) said yesterday it had received an order for another 29 million doses of its nasal spray vaccine for 2009 H1N1 influenza virus.
The deal was placed by the US Department of Health and Human Services
(HHS).
In total, HHS has ordered more than 40 million doses of MedImmune’s live attenuated influenza vaccine (LAIV), worth a combined USD453m. Earlier orders for around 13 million doses were awarded in May and July.
The vaccine was approved by the US Food and Drug Administration
(FDA) on 15 September 2009 and is indicated for the active immunisation of persons aged from two to 49 years against influenza caused by pandemic (H1N1) 2009 virus, or swine flu.
MedImmune started to develop LAIV for this strain of H1N1 in late April, when the company received the novel virus from the US Centers for Disease Control and Prevention (CDC).
http://www.tradingmarkets.com/.site/news/Stock%20News/2540206/
It looks very much like “they” they are now publicly and very carefully walking themselves back from the live/attenuated virus, leading me to believe this Navy story
What makes up the Influenza A (H1N1) 2009 Monovalent vaccines?
The Influenza A (H1N1) 2009 monovalent vaccines are manufactured using the same approved processes used to produce the seasonal influenza vaccines. Ingredients used during the manufacture of influenza vaccines include substances to help prevent bacterial contamination, to inactivate or “kill” the viruses, and stabilizers to prevent the vaccine from changing. Vaccines that are packaged in multi-dose vials use a preservative to prevent contamination. The Influenza A (H1N1) 2009 Monovalent vaccines are made from a single influenza virus strain that is an A/California/7/09-like virus. For the injectible vaccines, or shots, the virus is inactivated, using the same processes the manufacturers use for seasonal influenza vaccines. The vaccine administered via nasal spray contains a live, attenuated virus.
People who have a severe (life-threatening) allergy to chicken eggs, or to any other substance in the vaccine, should not be vaccinated.
One of my rare, everyone pings